Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids

CMS sets $1,000 supply code for TearCare SmartLids, but reimbursement impact remains uncertain.

What the company is saying

Sight Sciences is highlighting the establishment of CMS supply code SD397 for its TearCare SmartLids, with an assigned price of $1,000 effective January 1, 2027. The company frames this as a step toward greater transparency and potential for more consistent reimbursement for TearCare procedures. CEO Paul Badawi emphasizes the importance of a validated, nationally recognized supply valuation and expresses appreciation for CMS’s decision. The announcement details the clinical use of TearCare SmartLids in procedures reported under CPT code 0563T, clarifying that this code remains carrier-priced and the new supply code does not guarantee a national Medicare payment rate or separate reimbursement. The company also references its OMNI and SION Surgical Systems and regulatory clearances for its products. The tone is optimistic, focusing on regulatory progress while acknowledging that actual payment determinations will depend on payer policies.

What the data suggests

CMS has established supply code SD397 for TearCare SmartLids with a price of $1,000, effective January 1, 2027, as part of the CY 2027 Medicare Physician Fee Schedule Final Rule. This code applies to the single-use component used in the TearCare procedure, which is reported under CPT code 0563T for bilateral evacuation of meibomian glands. The new code provides a benchmark for direct practice expense but does not set a national Medicare payment rate or guarantee reimbursement, as CPT 0563T remains carrier-priced. Payment for the procedure will still depend on individual payer coverage and reimbursement policies. The announcement does not disclose any realized financial impact, revenue, or volume data attributable to the new code. The only hard figure is the $1,000 assigned price, which is a reference for supply valuation rather than a direct revenue line. No evidence is provided that payers will adopt this price or that provider reimbursement will increase as a result.

Analysis

The announcement is generally factual, disclosing that CMS has established a new supply code and assigned a price for the TearCare SmartLids, effective January 1, 2027. This is a concrete regulatory milestone, but the headline and executive commentary emphasize potential future benefits—such as 'greater transparency' and 'more consistent reimbursement over time'—that are not yet realized and remain subject to payer policies. The only forward-looking claim is that the new code 'can support more transparent and consistent reimbursement for TearCare procedures over time,' which is aspirational and not guaranteed. No financial performance metrics (revenue, profit, margins) are disclosed, so the true_signal cannot exceed weak_positive. The effective date is over a year away, and the announcement does not establish a national Medicare payment rate or guarantee reimbursement, limiting immediate impact.

Risk flags

• ●There is no guarantee that payers will adopt the $1,000 supply code or reimburse at this level, as payment determinations remain subject to individual payer policies. This creates uncertainty around the actual financial impact for providers and the company.
• ●CPT code 0563T remains carrier-priced, meaning there is no national Medicare payment rate or separate reimbursement established for the TearCare SmartLids. Providers may face inconsistent reimbursement, limiting near-term uptake or revenue growth.
• ●The announcement does not provide evidence of payer adoption, realized reimbursement, or increased procedure volumes resulting from the new code. The absence of such data means the potential benefits are speculative until actual market behavior is observed.

Bottom line

CMS’s establishment of a $1,000 supply code for TearCare SmartLids is a regulatory milestone, but it does not guarantee reimbursement or immediate financial upside for Sight Sciences. The code provides a reference point for direct practice expense, yet payment for the TearCare procedure will still depend on individual payer policies, and CPT 0563T remains carrier-priced. No data is provided on payer adoption, realized reimbursement, or procedure volumes, so the announcement’s impact is aspirational rather than concrete. Investors should recognize that the effective date is over a year away and that the financial benefits, if any, will only materialize if payers choose to reimburse at or near the assigned price. The most important takeaway is that while the code assignment is a step forward in reimbursement transparency, its commercial impact remains unproven until payers and providers respond.

Announcement summary

(NASDAQ:SGHT) Sight Sciences, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a new direct practice expense supply code for the single-use TearCare SmartLids component of the TearCare System. The new supply code is SD397, and CMS has assigned it a price of $1,000 effective January 1, 2027. This code and price are part of the CY 2027 Medicare Physician Fee Schedule (PFS) Final Rule. The TearCare SmartLids are used in procedures reported with CPT code 0563T for bilateral evacuation of meibomian glands using heat delivered through wearable, open-eye eyelid treatment devices, followed by manual gland expression. CPT 0563T remains carrier-priced, and the new supply code does not establish a national Medicare payment rate or separate reimbursement for SmartLids. Payment determinations for the procedure remain subject to applicable payer coverage and reimbursement policies. Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences, stated that establishing a validated, nationally recognized supply valuation for TearCare provides greater transparency into an important direct practice expense associated with the procedure and can support more transparent and consistent reimbursement for TearCare procedures over time. The TearCare SmartLids adhere to the tarsal plates of the upper and lower eyelids and deliver a clinically-proven, highly precise, and software-controlled therapeutic temperature to melt meibomian gland obstructions while allowing patients to blink during treatment. The Sight Sciences Market Access team is available to assist with coverage, coding, and payment questions. The OMNI Surgical System is an implant-free, minimally invasive glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma and is CE Marked for use in the European Union. The SION Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The TearCare System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.

Disagree with this article?